Sarah Jones, MD
Neurology · Charlottesville, VANPI 1245474709
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Sanofi at 40.0% of the total. That places this record below the midpoint for neurology clinicians in VA, where the typical reported total is $1,288.
Across 5 payments — averaging $69.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$138
- CSL Behring$100
- Biogen$92
- UCB, Inc.$16
Across 15 payments — averaging $8301.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$98K
- Argenx US, Inc.$25K
- UCB Biosciences Inc.$2K
What the payments were for
- Food & beverage$15545%
- Education$19255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $138 |
| CSL Behring | 1 | $100 |
| Biogen | 2 | $92 |
| UCB, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kcentra$100
How this compares
$347 in reported general payments places this provider in the 30th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 44 | $1,370,597 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $481,036 |
| Nurtec OdtRimegepant Sulfate | 11 | $52,309 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $44,041 |
| QuliptaAtogepant | 12 | $35,962 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 28 | $10,929 |
| Mycophenolate Mofetil | 42 | $5,429 |
| Pyridostigmine Bromide | 35 | $2,024 |
| Gabapentin | 66 | $1,992 |
| Azathioprine | 23 | $1,256 |
| Zonisamide | 25 | $1,010 |
| Baclofen | 39 | $717 |
| Topiramate | 15 | $596 |
| Lamotrigine | 19 | $532 |
| Pregabalin | 33 | $502 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlottesville
- Robert ShinCharlottesville$1.7M
- Brian WeinshenkerCharlottesville$195K
- Robert SawyerCharlottesville$55K
- Nathan FountainCharlottesville$45K
- Helen Dainton-HowardCharlottesville$41K
- Alissa HiginbothamCharlottesville$37K
- Ramsey FalconerAlexandria$2M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.